Abstract
We have seen an explosion of interest and endeavor in the field of biomarker research in recent years. However, we are only just beginning to see the benefits within the clinic. The next decade will see a massive increase in our understanding and in the true utility of biomarkers in healthcare, and the advances will be driven both by the inspiring opportunities from a patient perspective and also by economic and commercial imperatives. As biomarker research and applications evolve, Biomarkers in Medicine will provide a critical overview of the advances and explore their potential relevance in the clinical setting. The conception and launch of Biomarkers in Medicine has been a stimulating and enjoyable experience for all of the team involved and I must thank Scott Waldman for his enlightening insights only 1 year ago that led to the inception of this multidisciplinary journal. Some of the clearest illustrations of the value of biomarkers have can be seen within the oncology field. However, future potential spans a range of therapeutic areas, and Senior Editors Scott Waldman and Andre Terzic have together established an outstanding editorial advisory team who are representative of this multidisciplinary focus and are drawn from a range of organizations with a stake in biomarker research, including academia, clinical centers, the pharmaceutical industry, regulatory organizations and biotechnology. I would like to thank the Editorial Board for their continued support and advice as the project has developed. The Senior Editors, Editorial Board and publishing team alike are delighted with the launch issue and we all give our thanks to the authors who have contributed and placed their trust in this new venture. I should emphasize that each of the articles we publish is subject to peer review by three independent experts and thanks must also go to our referees for their timely and constructive comments. Over the past year, we have established stimulating and rewarding relationships within a vibrant and diverse community, and I hope that these are the first of many.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
